ReviewJournal of leukocyte biology2019

JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy.

Elisa Gremese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.